294 related articles for article (PubMed ID: 18834693)
1. NK cell-mediated lysis is essential to kill Epstein-Barr virus transformed lymphoblastoid B cells when using rituximab.
Markasz L; Vanherberghen B; Flaberg E; Otvös R; Stuber G; Gustafsson Jernberg A; Olah E; Skribek H; Szekely L
Biomed Pharmacother; 2009 Jul; 63(6):413-20. PubMed ID: 18834693
[TBL] [Abstract][Full Text] [Related]
2. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells.
Markasz L; Stuber G; Flaberg E; Jernberg AG; Eksborg S; Olah E; Skribek H; Szekely L
BMC Cancer; 2006 Nov; 6():265. PubMed ID: 17101045
[TBL] [Abstract][Full Text] [Related]
4. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
[TBL] [Abstract][Full Text] [Related]
5. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
6. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
[TBL] [Abstract][Full Text] [Related]
7. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.
Golay J; Manganini M; Facchinetti V; Gramigna R; Broady R; Borleri G; Rambaldi A; Introna M
Haematologica; 2003 Sep; 88(9):1002-12. PubMed ID: 12969808
[TBL] [Abstract][Full Text] [Related]
8. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.
van Meerten T; van Rijn RS; Hol S; Hagenbeek A; Ebeling SB
Clin Cancer Res; 2006 Jul; 12(13):4027-35. PubMed ID: 16818702
[TBL] [Abstract][Full Text] [Related]
9. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
[TBL] [Abstract][Full Text] [Related]
10. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
[TBL] [Abstract][Full Text] [Related]
11. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
[TBL] [Abstract][Full Text] [Related]
12. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells.
Fischer L; Penack O; Gentilini C; Nogai A; Muessig A; Thiel E; Uharek L
Exp Hematol; 2006 Jun; 34(6):753-9. PubMed ID: 16728280
[TBL] [Abstract][Full Text] [Related]
13. Responses to rituximab vary among follicular lymphoma B cells of different maturation stages.
Mattila AM; Meri S
Scand J Immunol; 2008 Aug; 68(2):159-68. PubMed ID: 18702746
[TBL] [Abstract][Full Text] [Related]
14. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
[TBL] [Abstract][Full Text] [Related]
15. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab.
Carnahan J; Stein R; Qu Z; Hess K; Cesano A; Hansen HJ; Goldenberg DM
Mol Immunol; 2007 Feb; 44(6):1331-41. PubMed ID: 16814387
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum.
Lefebvre ML; Krause SW; Salcedo M; Nardin A
J Immunother; 2006; 29(4):388-97. PubMed ID: 16799334
[TBL] [Abstract][Full Text] [Related]
17. Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms.
Voso MT; Pantel G; Rutella S; Weis M; D'Alò F; Urbano R; Leone G; Haas R; Hohaus S
Haematologica; 2002 Sep; 87(9):918-25. PubMed ID: 12217803
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate reduces rituximab-induced tumor-growth inhibition in vivo on Epstein-Barr virus-associated human B-cell lymphoma.
Némati F; Mathiot C; Grandjean I; Lantz O; Bordier V; Dewulf S; Ekue R; Di Santo JP; Poupon MF; Decaudin D
Anticancer Drugs; 2007 Oct; 18(9):1029-37. PubMed ID: 17704653
[TBL] [Abstract][Full Text] [Related]
19. Cell cycle arrest and lytic induction of EBV-transformed B lymphoblastoid cells by a histone deacetylase inhibitor, Trichostatin A.
Seo JS; Cho NY; Kim HR; Tsurumi T; Jang YS; Lee WK; Lee SK
Oncol Rep; 2008 Jan; 19(1):93-8. PubMed ID: 18097580
[TBL] [Abstract][Full Text] [Related]
20. Suppressive effect of human natural killer cells on Epstein-Barr virus-induced immunoglobulin synthesis.
Kuwano K; Arai S; Munakata T; Tomita Y; Yoshitake Y; Kumagai K
J Immunol; 1986 Sep; 137(5):1462-8. PubMed ID: 3018077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
